BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Mental Health

Otsuka Advances Centanafadine With FDA Filing To Bring a First in Class ADHD Therapy to Children, Adolescents, and Adults

Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents, and adults. It is a first-in-class norepinephrine, dop...

November 26, 2025 | News

Akeso Receives NMPA Clearance to Initiate Clinical Trials for China’s First Bispecific Antibody for Alzheimer’s Disease

Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aβ) and blood-brain barrier (BBB) expre...

November 18, 2025 | News

Lundbeck’s Bexicaserin Receives Breakthrough Therapy Designation in China for Severe Childhood Epilepsies

Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies Novel 5HT2C mechanism des...

October 14, 2025 | News

How to Communicate Treatment Plans to Mental Health Patients

In the US, more than 57 million adults are currently dealing with some form of mental illness. Every year, this number keeps increasing, indicating a growi...

September 18, 2025 | News

South Korea’s Neurophet Signs MoU with InRAD to Advance Global Standards for Alzheimer’s and Dementia Data

Neurophet's AI-based brain imaging analysis solutions to support global standardization of Alzheimer's and other dementia-related data Enhancing dementi...

September 03, 2025 | News

Genentech and Alnylam Advance Zilebesiran into Phase III Outcomes Trial for Hypertension

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 – – ...

September 02, 2025 | News

AbbVie To Acquire Gilgamesh’s Lead Psychedelic Compound Bretisilocin For Up To $1.2 Billion

Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of m...

August 26, 2025 | News

Avive Health and Emyria Partner to Open Queensland’s First Empax Clinic for PTSD and Depression

Avive Health ("Avive"), an Australian-owned private mental health provider, has announced a major national partnership with Emyria Limited (ASX: EMD), mark...

August 14, 2025 | News

How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress

While innovation drives progress, the absence of consistent ethical safeguards in psychiatry can distort research outcomes and undermine clinical trials. S...

July 21, 2025 | News

The Importance of a Patient’s Mental Health During Clinical Trials

Most trial participants already have existing health issues. The added burden of trial participation can impact their emotional and psychological well-bein...

July 02, 2025 | Report

Infosys and Mental Health Foundation Australia Launch ‘Supportive Mind’ App to Promote Mental Well-Being Across ANZ

Infosys, a global leader in next-generation digital services and consulting, today announced a strategic collaboration with Mental Health Founda...

June 27, 2025 | News

Mental Health Tops Health Concerns in Singapore, Surpassing Cancer and COVID-19

High demand: Mental health now tops health concerns in Singapore, surpassing cancer and COVID-19. New regional hub: MHIN Asia Hub, based in Si...

February 18, 2025 | News

Biotropics Malaysia Takes the Lead in Closing the Women’s Health Gap with Innovative Clinical Solutions

While gender parity has seen progress in recent years, the women's health gap remains significant. Women, despite comprising half of the global labor force...

December 30, 2024 | News

Tessara Therapeutics, Psylo, and University of Sydney Secure $6.2M to Advance Neuroplastogen Research for Methamphetamine Addiction

Tessara Therapeutics, Psylo, and the University of Sydney are pleased to announce their receipt of a $3 million Cooperat...

October 29, 2024 | News

Stay Connected